
By Carolee Lee, CEO/Founder Women’s Health Access Matters (WHAM)
Big, visible trends are all around us: AI. Big data. Explosive technology growth.
There are more big trends which hide in plain sight: Women are 51 per cent of the U.S. population. Women live longer than men.
Women are much more likely than men to experience certain diseases and disorders like dementia, and experience cardiac arterial disease and lung cancer quite differently.
Trends like these translate into big economic opportunity.
The longstanding underrepresentation of women in health research means there is big economic opportunity today, especially in the specific health areas where women are particularly affected.
WHAM has done the maths on just how big the economic opportunity could be.
WHAM is a nonprofit organisation working to increase awareness of and accelerate funding for women’s health research to transform women’s lives.
We commissioned the RAND Corporation to conduct a series of studies that examine the impact of accelerating sex–based health research on women, their families, and the economy, examining in depth rheumatoid arthritis (autoimmune), Alzheimer’s disease (brain), coronary artery disease (heart) and lung cancer (cancer).
The WHAM Report: The Case to Fund Women’s Health Research highlights findings across the first three diseases in one brief report.
The findings are clear.
Because women are impacted disproportionately by certain health issues, differently from men for others, and exclusively affected by some, there is tremendous current investment opportunity.
Whenever I talk about The WHAM Report and its findings, people are astonished.
They ask, why isn’t there more research on these issues that impact women’s health research so profoundly, especially given the power of women to drive the economy?
All women who live long enough go through menopause, but when we say the words “women’s health” we mean a lot more than women’s ovaries.
We mean that 9 of 10 Lupus cases are women. We mean that 2/3 of Alzheimer’s patients are women. We mean that women are 50 per cent more likely than men to die in the year after a cardiac event.
Of the 1 in 5 U.S. population who are afflicted with an autoimmune disorder, women are 4 out of 5 of those. That’s 80 per cent of some 50 million people for autoimmune disorders alone.
The economic opportunity in these disease areas is outsized: to date, women have barely been included in the vital research which improves health outcomes.
Women represent $15 out of every $100 invested in lung cancer, even though lung cancer is the number one cancer killer of women.
Women represent $7 out of every $100 invested in rheumatoid arthritis research, even though they are 60 – 80 per cent of the patients.
Women represent $12 out of every 100 spent on Alzheimer’s and related disorders research, though women are 66 per cent of the patients.
Women represent less than $5 out of every $100 spent on cardiovascular research, although coronary arterial disease is the number one killer of women.
The WHAM Report estimates the potential gains in detail, using microsimulation models which were vetted by a diverse panel of experts.
The case for funding women’s health is clear: if we invest $350 million in women’s health research across just four diseases, we get $14 billion in returns to our economy.
Many of us believe ageing – just the act of getting older — means more health issues, plain and simple. Maybe it does.
Perhaps because of that, living well for longer is practically a national movement, especially for women.
Meanwhile, women are about to be the beneficiaries of the biggest wealth transfer in U.S. history.
As the number of women — and of ageing and wealthy women in particular — continues to grow in the U.S., there is going to be greater demand for solutions to the health challenges that affect women in outsized numbers.
Healthcare systems, physicians, and employers alike need those solutions — not to mention the individuals whose quality of life and productive employability are impacted.
These disorders drive women out of productive work, whether because they have inadequate treatment options or are caring for their families.
The research that can develop therapies that are truly precision medicine is technology driven.
Femtech leaders, innovators, clinicians, researchers, patient advocates and investors — all have a role to play in developing, bringing to market, and deploying transformative therapies that keep women in the workforce and live well.
We know that research works.
Lung cancer is the #1 cause of cancer death in women, killing 150 per cent as many women as breast cancer. Non-smoking women are twice as likely to get lung cancer as non-smoking men.
Yet perhaps because $7 was spent on research that included men for every $1 of research that included women, lung cancer diagnoses for men have fallen by 36 per cent even as women’s lung cancer diagnoses have risen by 84 per cent.
To repeat: research works.
When a woman has a cancer diagnosis, as much as she may try to keep everything “normal” for herself and her family, the reality is that her labor productivity is negatively impacted as her healthcare costs rise.
Ditto for when a woman has an autoimmune disorder diagnosis, or has a cardiac event.
Her new normal is constrained labour productivity and growing healthcare costs.
And even if she doesn’t have the diagnosis for Alzheimer’s or related dementias, nearly 2 million women have been pulled out of the workforce to care for loved ones – whether parents, or partners – because there are no really good and cost-effective options for care.
In 2020, Alzheimer’s cost the economy $305 billion dollars. Some of that funded employment, in caregiver fields already notoriously under-capacitated.
$305 billion dollars is nearly $1000 per person, for every single individual in the U.S.
Isn’t that money we want to transfer back into the economy in the form of returns on investment?
Outsized gains can be realised because of the sex-based disease and outcome disparities.
WHAM’s findings of a $14 billion return on $350 million invested underscore that now is the time to double down on investment with an eye towards returns – financial, economic, and in individual quality of life.
Join the movement. Invest in making change for the health of women.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.










